About: Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: An Asia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: An Asia–Pacific perspective Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: An Asia–Pacific perspective
Source	Medline; PMC
abstract	Abstract: Chronic obstructive pulmonary disease (COPD) is a major public health problem and its prevalence and mortality are increasing throughout the world, including the Asia–Pacific region. To arrest these worldwide trends, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Expert Panel's global strategy for the diagnosis, management, and prevention of COPD was published in 2001. Based on recently published clinical trials, the GOLD statement was updated in 2003. The Asia–Pacific COPD Roundtable Group, a taskforce of expert respirologists from the Asia–Pacific region, has recently formulated a consensus statement on implementation of the GOLD strategy for COPD in the Asia–Pacific region. The key issues identified by the COPD Roundtable Group for comment are: (i) where there is no access to spirometry, diagnosis of COPD could be suspected on the basis of history, symptoms and physical signs; (ii) inhaled bronchodilators are the preferred regular treatment for COPD in the region, but oral bronchodilators may be considered if the cost of inhaled bronchodilators is a barrier to treatment; (iii) the use of an Metered Dose Inhaler with spacer in place of a nebulizer is recommended in the treatment of acute airflow obstruction in patients with COPD; (iv) influenza vaccination is recommended for all patients with COPD in communities where there is a high likelihood of Severe Acute Respitory Syndrome; and (v) simplified pulmonary rehabilitation programmes should be established in areas where comprehensive programmes are unavailable. Physical exercise training and education on smoking cessation should be core elements of any rehabilitation program. In summary, the COPD Roundtable Group supports implementation of the GOLD strategy for the diagnosis, management and prevention of COPD in the Asia–Pacific region, subject to the additions and modifications to the guidelines suggested above.
has issue date	2005-02-03(xsd:dateTime)
bibo:doi	10.1111/j.1440-1843.2005.00692.x
bibo:pmid	15691232
has license	no-cc
sha1sum (hex)	cd62b1c0ef2fe7d9f56c976ed23282b5a09d4abf
schema:url	https://doi.org/10.1111/j.1440-1843.2005.00692.x
resource representing a document's title	Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: An Asia–Pacific perspective
has PubMed Central identifier	PMC7169139
has PubMed identifier	15691232
schema:publication	Respirology
resource representing a document's body	covid:cd62b1c0ef2fe7d9f56c976ed23282b5a09d4abf#body_text
is schema:about of	named entity 'history' named entity 'vaccination' named entity 'core' named entity 'Syndrome' named entity 'clinical trials' named entity '2001' named entity 'rehabilitation' named entity 'worldwide' named entity 'prevention' named entity 'SYNDROME' named entity 'REHABILITATION PROGRAM' named entity 'SUMMARY' named entity 'REGULAR' named entity 'GUIDELINES ' named entity 'IDENTIFIED BY' covid:arg/cd62b1c0ef2fe7d9f56c976ed23282b5a09d4abf named entity 'major' named entity 'COPD' named entity 'arrest' named entity 'Expert' named entity 'prevalence' named entity 'influenza' named entity 'COPD' named entity 'nebulizer' named entity 'prevention' named entity 'Roundtable' named entity 'inhaled bronchodilators' named entity 'symptoms' named entity 'programmes' named entity 'COPD' named entity 'Panel' named entity 'Roundtable' named entity 'acute' named entity 'Inhaler' named entity 'published' named entity 'COPD' named entity 'Respirology' named entity 'pulmonary rehabilitation' named entity 'Physical exercise' named entity 'clinical trials' named entity 'COPD' named entity 'smoking cessation' named entity 'Metered Dose Inhaler' named entity 'COPD' named entity 'Asia-Pacific' named entity 'inhaled bronchodilators' named entity 'Chronic Obstructive Lung Disease' named entity 'Asia-Pacific' named entity 'Asia-Pacific' named entity 'Chronic Obstructive Lung Disease' named entity 'chronic obstructive pulmonary disease' named entity 'COPD' named entity 'nebulized' named entity 'risk factors' named entity 'cost-effectiveness' named entity 'MDI' named entity 'COPD' named entity 'MDI' named entity 'COPD' named entity 'Clinical data' named entity 'met 1' named entity 'spirometry' named entity 'COPD' named entity 'COPD' named entity 'scientific evidence' named entity 'health education' named entity 'adverse effects' named entity 'risk factors' named entity 'COPD' named entity 'exercise training' named entity 'pulmonary rehabilitation' named entity 'COPD' named entity 'clinically significant' named entity 'Asian' named entity 'bronchodilators' named entity 'Dyspnoea' named entity 'COPD' named entity 'COPD' named entity 'exercise capacity' named entity 'WHO' named entity 'clinical management' named entity 'Asia-Pacific'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software